Prophylaxis of invasive fungal infection in immunocompromised patients such as stem cell transplant recipients
Treatment of invasive fungal infections such as candidiasis if conventional therapy has failed
Laboratory
Clinical
Posaconazole is an inhibitor and is metabolized by cytochrome P4503A4; therefore, coadministration with other agents that are cytochrome P450 substrates, inducers, or inhibitors will result in significant drug interactions.
You must check for potential drug interactions when initiating Posaconazole therapy or starting a new medication in patients already receiving Posaconazole therapy.
Administration of the following agents with Posaconazole is contraindicated:
Posaconazole inhibits metabolism of the following agents. Dose reductions and close monitoring are recommended when Posaconazole is used with agents concomitantly:
High pharmacokinetic variability, dependent on fatty food administration (for solution).
The two oral formulations of posaconazole (delayed-release tablets and an oral suspension) are not interchangeable, and cannot be directly substituted without a change in dosage.
All orders for posaconazole must specify the dosage form, strength, and frequency
Antimicrobial class: azole
Pregnancy category: C